Combination of CSFR1 inhibitor (PLX3397 or anti–CSF1R Ab) with anti-PD1 reduced TAM numbers, enhanced CD8 T cell infiltration, and consequently decreased tumor size [157,158]. Here, CD8A is linked to neoplasm.